Invented at the US National Cancer Institute, photoimmunotherapy is so far approved only in Japan. Results from 17 Aomori patients and a later Phase 3 trial show what early approval gains and leaves unanswered.
On September 29, 2026, Japan's iPS cell heart sheet RiHEART reached its first insured patient. It costs 53.2 million yen, and two of eight trial patients met its main goal. Now 75 cases must show it works.
A Yonezawa ryokan is asking guests not to book it on Agoda. Rooms sold outside a hotel's control caused trouble in Taiwan, Vietnam and Europe years ago, and Agoda tops a Korean complaint tally with 2,190 cases.
After a suspected core member was sent from Osaka to Germany, Qilin called Japan's security among the world's worst, without evidence. Japan's new reporting law is narrower than the EU's NIS2.
Japan's gene-edited GABA tomato opened its field. It wasn't the first gene-edited food sold (US soybean oil, 2019), but the first CRISPR food shoppers could buy. How Japan's rules compare with the EU's.
Japan made 'mottainai' a global word, yet its restaurants often refuse to box up leftovers. A 2024 government guideline shows why: legally, you are meant to eat it on the premises.
Japan had 2,730 sento left at the end of fiscal 2024. Under a 1946 ordinance, prefectures still cap their prices, and Tokyo calculates its cap like a utility rate. It rose to 600 yen in August 2026.
Japan's AMAGOI moonshot starts field trials over Toyama Bay in December 2026, seeding winter snow clouds with dry ice. Its own published flight log shows how hard it is to prove anything worked.
GO, Waymo and Nihon Kotsu want driverless taxis in Tokyo in 2027. Japan has had a permit regime since 2023, but the permits granted so far cover fixed lines: a 2 km cart route, a 700 m shuttle, a busway.